Effects of Sleep Disruption on Drug Response
Status: | Not yet recruiting |
---|---|
Conditions: | Back Pain, Back Pain, Healthy Studies |
Therapuetic Areas: | Musculoskeletal, Other |
Healthy: | No |
Age Range: | 21 - 60 |
Updated: | 11/28/2018 |
Start Date: | April 1, 2019 |
End Date: | May 1, 2021 |
Contact: | Patrick H. Finan, Ph.D. |
Email: | pfinan1@jhu.edu |
Phone: | 410-550-7901 |
The central scientific premise of the proposed study is that sleep disruption (SD) will
influence individuals' subjective response to blinded medication administration. The
investigators further believe these responses will vary among patients who have chronic low
back pain (CLBP) vs. healthy controls, and that sex will moderate effects.
The proposed study evaluates whether CLBP patients' subjective responses to study medication
administration are altered by SD. The investigators focus on two outcome domains: abuse
liability (i.e., drug liking and valuation) and response to pain testing.
The investigators propose a mixed between-within randomized crossover human-laboratory
experiment that investigates placebo-controlled effects of study medication on 1) abuse
liability metrics (Drug Liking and Monetary Valuation) and 2) response to laboratory-evoked
standardized pain measures, after one night of uninterrupted sleep (US) and again after one
night of SD. The investigators will recruit both CLBP patients (N = 60) and healthy controls
(N = 60).
influence individuals' subjective response to blinded medication administration. The
investigators further believe these responses will vary among patients who have chronic low
back pain (CLBP) vs. healthy controls, and that sex will moderate effects.
The proposed study evaluates whether CLBP patients' subjective responses to study medication
administration are altered by SD. The investigators focus on two outcome domains: abuse
liability (i.e., drug liking and valuation) and response to pain testing.
The investigators propose a mixed between-within randomized crossover human-laboratory
experiment that investigates placebo-controlled effects of study medication on 1) abuse
liability metrics (Drug Liking and Monetary Valuation) and 2) response to laboratory-evoked
standardized pain measures, after one night of uninterrupted sleep (US) and again after one
night of SD. The investigators will recruit both CLBP patients (N = 60) and healthy controls
(N = 60).
Inclusion Criteria:
General Inclusion Criteria:
- 21-60 years old
- A stable sleep phase within 21:00 and 09:00
- Total sleep time >6 and <8.5 hours/night
- Sleep efficiency >80%
- Less than 2 servings/day of caffeinated beverages and willing to discontinue 3 days
prior to admission.
CLBP-Specific Inclusion Criteria:
- Have a physician-confirmed diagnosis of CLBP
- Report chronic low back pain.
Exclusion Criteria:
General Exclusion Criteria:
- BMI >35
- Significant medical or psychiatric morbidity within 6 months or lifetime history of
bipolar disorder, psychotic disorder, seizure disorder
- Lifetime history of alcohol or substance use disorder including opioid use disorder
- Clinically significant abnormal complete blood count or comprehensive metabolic
profile
- Any contraindicated medical condition (status asthmaticus; chronic obstructive
pulmonary disease; reduced respiratory function; hypotension; hypertension; impairment
of hepatic, pulmonary or renal functions; myxedema or hyperthyroidism; adrenocortical
insufficiency; gastrointestinal obstruction; gall bladder disease; acute alcoholism;
history of convulsive disorders; history of head injury)
- Current use of stimulants, opioids, benzodiazepines or other Central Nervous System
(CNS) depressant
- Positive toxicology screen for opioids, stimulants, or recreational drugs
- Pregnancy or lactation
- Significant preadmission psychological distress.
Healthy Control and CLBP-Specific Exclusion Criteria:
- Report current medical/psychiatry history
- Report acute painful injury (within 3 months)
- Have a diagnosed chronic pain disorder.
We found this trial at
1
site
Click here to add this to my saved trials